Portfolio of Companies
NanoCellect’s game changing technology offers unique solutions to barriers imposed by current state of the art flow cytometers. We use microfluidics with an integrated sorting system that immensely simplifies the process of analyzing and sorting distinct populations of cells from a heterogeneous population. Dr. Morachis serves as CEO and PI on multiple SBIR grants. NanoCellect has raised over $6.1M in SBIR funding from the NIH. Status: Active.
Metabolus discovers biomarkers for complex diseases for which genetic markers have not proven reliable. Their discovery platform has identified biomaker panels for Post-Traumatic Stress Disorder (PTSD), Traumatic Brain Injury (TBI), and Autism Spectrum Disorder. Currently seeking investment.
SweetSpot Diabetes is a health technology company focused on improving the use of data in diabetes treatment and research. By providing a universal platform with massive computational capacity, SweetSpot makes it feasible to gather and analyze patient device data that is currently discarded. SweetSpot is a game changer for patients, physicians, payors, pharma and other researchers. Status: Exited (Acquired by Dexcom).
Arima is developing next generation sequencing technology that allows maternal and paternal chromosomes to be sequenced, or haplotype phased. Status: Active.
Novoron is conducting experiments to demonstrate proof of principle experiments for LRP-1 mediated axon regeneration. The technology being developed can have tremendous value to spinal cord regeneration.
Sonrgy’s primary goal is the development of its proprietary drug delivery platform. Initially conceived by researchers at UC San Diego Moores Cancer Center, Sonrgy’s core technology is a revolutionary form of chemotherapy which aims to improve both quality of life and survival time for millions of cancer patients. The system combines a breakthrough nanotechnology with a focused beam of ultrasound to directly target tumors for drug release.